| CREX | PRESS-RELEASE | bearish | 6/10 | Creative Realities reported Q1 2026 revenue of $16.3M (+68% YoY), beating the $16.5M consensus by a narrow margin, but p | May 15, 2026 |
| PVLA | PRESS-RELEASE | bullish | 7/10 | Palvella presented positive Phase 2 TOIVA data at SID showing QTORIN rapamycin statistically significantly reduced bleed | May 15, 2026 |
| ANVS | PRESS-RELEASE | bearish | 6/10 | Annovis Bio reported Q1 2026 EPS of -$0.63, significantly below the -$0.35 consensus estimate, with R&D expenses triplin | May 15, 2026 |
| LMFA | PRESS-RELEASE | bearish | 7/10 | LMFA reported Q1 2026 revenue of $2.1M (-11% YoY) and a GAAP EPS of -$1.33, a 504.5% miss vs consensus of -$0.22. The ne | May 15, 2026 |
| CECO | PRESS-RELEASE | neutral | 3/10 | CECO and Thermon set a May 22, 2026 deadline for Thermon stockholders to elect merger consideration (stock, cash, or mix | May 15, 2026 |
| MSLE | PRESS-RELEASE | neutral | 4/10 | Satellos Bioscience reported a Q1 2026 net loss of $9.8M ($0.53 per share), wider than the $6.1M loss a year ago, driven | May 15, 2026 |
| INDP | PRESS-RELEASE | bearish | 8/10 | Indaptus Therapeutics reported Q1 2026 results with a net loss of $2.5M ($0.23/share), improved from $4.5M ($9.11/share) | May 15, 2026 |
| PPBT | PRESS-RELEASE | neutral | 4/10 | Purple Biotech reported Q1 2026 net loss of $0.1M, significantly narrower than the $0.5M loss in Q1 2025, driven by $2.2 | May 15, 2026 |
| BTAI | PRESS-RELEASE | bearish | 6/10 | BioXcel Therapeutics reported Q1 2026 EPS of -$0.54 (GAAP) vs consensus -$0.48, a -12.5% miss, with IGALMI revenue of $2 | May 15, 2026 |
| TRAW | PRESS-RELEASE | mixed | 5/10 | Traws Pharma reported Q1 2026 results with a net loss of $7.1M (-$0.53 EPS, beating the -$0.56 consensus) and zero reven | May 15, 2026 |
| TIL | PRESS-RELEASE | neutral | 4/10 | Instil Bio reported Q1 2026 GAAP EPS of -$0.62, in line with the consensus estimate of -$0.59 (within the ±2% threshold) | May 15, 2026 |
| KYMR | PRESS-RELEASE | neutral | 4/10 | Kymera Therapeutics announced that KT-621 Phase 1b atopic dermatitis data will be presented at SID and ATS conferences, | May 15, 2026 |
| TARA | PRESS-RELEASE | bullish | 7/10 | Protara Therapeutics announced positive updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-Naïve | May 15, 2026 |
| GNK | PRESS-RELEASE | bullish | 7/10 | Genco's board unanimously rejected Diana Shipping's unsolicited tender offer of $23.50 per share, calling it inadequate | May 15, 2026 |
| NUAI | PRESS-RELEASE | neutral | 4/10 | New Era Energy & Digital filed its Q1 2026 10-Q and announced a business update call for May 18. The press release highl | May 15, 2026 |
| CWEN | PRESS-RELEASE | neutral | 2/10 | Clearway Energy announced the retirement of EVP, General Counsel and Corporate Secretary Kevin P. Malcarney, effective J | May 15, 2026 |
| TLX | PRESS-RELEASE | neutral | 4/10 | Telix announced non-binding letters of intent to collaborate with EDAP TMS and Profound Medical, exploring the use of it | May 15, 2026 |
| HTHT | PRESS-RELEASE | bearish | 5/10 | H World reported Q1 2026 revenue of RMB6.0B ($870M), up 11.1% YoY, driven by 537 new hotel openings in China and 4.5% bl | May 15, 2026 |
| SPRY | PRESS-RELEASE | bearish | 6/10 | ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M, beating the $22.1M consensus, with neffy U.S. net product | May 15, 2026 |
| STLA.N | PRESS-RELEASE | bullish | 6/10 | Stellantis and Dongfeng Group signed a strategic cooperation agreement to expand their 34-year partnership, with the DPC | May 15, 2026 |
| GUAC | PRESS-RELEASE | neutral | 5/10 | Berto Acquisition Corp. II priced its IPO of 27,400,000 units at $10.00 per unit, raising $274 million to acquire an AI | May 14, 2026 |
| EXYN | PRESS-RELEASE | neutral | 5/10 | Exyn Technologies priced its IPO of 2.5M units at $7.75/unit, raising ~$19.4M in gross proceeds. The units consist of on | May 14, 2026 |
| BEEM | PRESS-RELEASE | neutral | 1/10 | Beam Global announced it will report its Q1 2026 results on May 15, 2026. | May 14, 2026 |
| VRM | PRESS-RELEASE | bearish | 6/10 | Vroom reported Q1 2026 results with a GAAP net loss of $19.6M attributable to common shareholders, compared to a Non-GAA | May 14, 2026 |
| IDACU | PRESS-RELEASE | neutral | 5/10 | Iron Dome Acquisition I Corp. priced its IPO of 15M units at $10/unit, expected to list on Nasdaq under IDACU starting M | May 14, 2026 |
| POET | PRESS-RELEASE | bullish | 7/10 | POET reported Q1 2026 revenue of $503K (up 202% YoY from $167K) but a net loss of $12.3M ($0.08/share), a significant mi | May 14, 2026 |
| CVCO | PRESS-RELEASE | neutral | 1/10 | Cavco Industries, Inc. announced it will report its fiscal Q4 2026 and full-year results on May 21, 2026. | May 14, 2026 |
| STEX | PRESS-RELEASE | neutral | 1/10 | Streamex Corp. announced it will host a conference call on May 20, 2026 to discuss its Q1 2026 results. | May 14, 2026 |
| HTLD | PRESS-RELEASE | neutral | 3/10 | Heartland Express reported Q1 2026 EPS of -$0.06, missing consensus estimates of $0.00 by a wide margin (surprise -2471. | May 14, 2026 |
| XELB | PRESS-RELEASE | bearish | 6/10 | Xcel Brands reported Q1 2026 revenue of $1.1M (-14% YoY) and a GAAP net loss of $2.5M (-$0.42/share), beating the consen | May 14, 2026 |